Nuvation Bio’s taletrectinib (Ibtrozi) gained FDA approval for metastatic non-small cell lung cancer with rare ROS1 mutations, showing durable responses including complete CNS disease resolution. This milestone provides an important option for a challenging patient subset with limited effective treatments.